SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC)

被引：0
|
作者：
Zhen, David Bing
Mayerson, Edward
Chiorean, E. Gabriela
Burgess, Earle F.
Swisher, Elizabeth M.
Gay, Carl Michael
Byers, Lauren Averett
Wistuba, Ignacio Ivan
Mahdi, Haider
Das, Satya
Starr, Jason S.
Othus, Megan
Chae, Young Kwang
Kurzrock, Razelle
机构：
[1] Univ Washington, Fred Hutchison Canc Res Ctr, Seattle, WA USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[4] Levine Canc Inst, Charlotte, NC USA
[5] Univ Washington, Sch Med, Seattle, WA USA
[6] UT MD Anderson Canc Ctr, Houston, TX USA
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA
[9] Cleveland Clin, Cleveland, OH USA
[10] Vanderbilt Univ Sch Med, Nashville, TN USA
[11] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA
[12] Northwestern Med Dev Therapeut Inst, Chicago, IL USA
[13] Med Coll Wisconsin Canc Ctr, Milwaukee, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4179
引用
收藏
页数：1
相关论文
共 9 条
  • [1] SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)
    Zhen, David Bing
    Moseley, Anna
    Chiorean, E. Gabriela
    Burgess, Earle F.
    Swisher, Elizabeth M.
    Gay, Carl Michael
    Byers, Lauren Averett
    Wistuba, Ignacio Ivan
    Mahdi, Haider
    Starr, Jason S.
    Othus, Megan
    Chae, Young Kwang
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC)
    Heymach, J.
    Glisson, B. S.
    Doebele, R. C.
    Huang, C.
    Gandara, D. R.
    Le Seoullier, S.
    Marotti, M. A.
    Camidge, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).
    William, William Nassib
    Feng, Lei
    Kies, Merrill S.
    Ahmed, Salmaan
    Blumenschein, George R.
    Glisson, Bonnie S.
    Massarelli, Erminia
    Johnson, Faye M.
    Lu, Charles
    Papadimitrakopoulou, Vassiliki
    Gold, Kathryn A.
    Theriault, Rachel Leigh
    Heymach, John
    Kim, Edward S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113.
    Sanborn, Rachel E.
    Patel, Jyoti D.
    Masters, Gregory A.
    Jayaram, Nagesh
    Stephens, Anthony W.
    Guarino, Michael J.
    Misleh, Jamal Ghazi
    Williams, Corinne E.
    Wu, Jingwei
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599
    Sandler, AB
    Gray, R
    Brahmer, J
    Dowlati, A
    Schiller, JH
    Perry, MC
    Johnson, DH
    LUNG CANCER, 2005, 49 : S31 - S31
  • [6] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599
    Sandler, AB
    Gray, R
    Brahmer, J
    Dowlati, A
    Schiller, JH
    Perry, MC
    Johnson, DH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090S
  • [7] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
    Otterson, G. A.
    O'Connor, P. G.
    Lin, M.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, Tom
    Raju, Robert N.
    Couch, Linda S.
    Kocs, Darren M.
    Jotte, Robert
    Wang Yunfei
    Bromund, Jane
    Marciniak, Martin D.
    Treat, Joseph
    Obasaju, Coleman K.
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S383 - S384
  • [9] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Obasaju, C. K.
    Raju, R. N.
    Stinchcombe, T.
    Couch, L. S.
    Jotte, R.
    Kocs, D. M.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
1